BrainStorm's Commitment to ALS Treatment
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is taking significant strides in the treatment of amyotrophic lateral sclerosis (ALS). The company is dedicated to its innovative therapy, NurOwn®, designed to provide patients with a viable treatment option.
Attention from Regulatory Bodies
Recently, the U.S. Food and Drug Administration (FDA) expressed its willingness to review a Citizen Petition that calls for a fresh examination of the data supporting NurOwn. This move is seen as an essential opportunity for BrainStorm to reestablish the efficacy of its treatment for ALS, an illness that has long been an area with limited therapeutic options.
Understanding the Citizen Petition
A Citizen Petition is a formal request submitted to the FDA, allowing any party to seek a specific regulatory action. This includes reviewing data or issuing guidelines. Through this process, BrainStorm is optimistic about highlighting the potential benefits of NurOwn to the FDA once again.
Commitment to Data Integrity
BrainStorm has always emphasized the importance of data integrity and scientific verification. Despite not participating in the petition's submission, the company welcomes this opportunity for a comprehensive review. They believe that in the continuously evolving regulatory landscape surrounding rare diseases, this assessment is paramount.
Collaboration with Regulatory Agencies
“We respect the FDA's independent review process and welcome its consideration of this request,” stated Chaim Lebovits, the President and CEO of BrainStorm. He reiterated the company’s commitment to uphold the scientific rigor and to work collaboratively with the FDA to develop effective therapies for ALS.
Ongoing Research and Development
To further validate NurOwn's effectiveness, BrainStorm remains focused on its Phase 3b clinical trial, known as the ENDURANCE trial, under an FDA Special Protocol Assessment. This trial is specifically designed to produce robust data that can substantiate the safety and efficacy of NurOwn in patients diagnosed with early-stage ALS.
Exploring Additional Pathways
In addition to conducting the trial, BrainStorm is exploring regulatory avenues that could facilitate immediate access to NurOwn for individuals suffering from ALS. This timely access is critical given the urgency faced by patients and their families.
Promising Survival Data
Recently, BrainStorm disclosed survival data from participants in its Expanded Access Program who had previously completed the Phase 3 clinical trial. This data is remarkable, showing that some participants survived more than five years from the onset of ALS symptoms, a significant improvement over typical survival estimates for this condition.
Link Between Treatment and Survival
This survival data suggests that the outcomes observed are unlikely to be coincidental, significantly underscoring the need for further exploration into the effects of NurOwn. Continued analysis and engagement with the ALS community also emphasize the importance of advocating for patient needs and scientific exploration.
Active Engagement with the ALS Community
BrainStorm is committed to maintaining transparency with the FDA and will continue to engage with clinicians, advocacy groups, and the ALS community. They aim to provide updates as new developments arise, ensuring that the community stays informed about the progress and prospects of NurOwn.
The Science Behind NurOwn Technology
The NurOwn technology platform utilizes autologous mesenchymal stem cells (MSCs) which are engineered to produce neurotrophic factors aimed at benefiting neurodegenerative diseases. By harnessing these unique properties, NurOwn aims to deliver essential biological signals to the damaged areas, with the goal of slowing or stabilizing disease progression.
The Future of BrainStorm and ALS Treatments
With a strong dedication towards ALS treatment, BrainStorm is also exploring innovations beyond NurOwn. They are advancing their allogeneic exosome-based platform designed for delivering therapeutic proteins and nucleic acids. Furthermore, BrainStorm holds a significant patent allowance for exosome technology, enhancing their intellectual property portfolio in regenerative medicine.
Frequently Asked Questions
What is NurOwn®?
NurOwn is an investigation therapy developed by BrainStorm, focusing on providing treatment for amyotrophic lateral sclerosis (ALS) using autologous stem cells.
What does the Citizen Petition entail?
The Citizen Petition is a formal request to the FDA for a new review of the evidence supporting NurOwn as a treatment for ALS, emphasizing the need for regulatory re-evaluation.
What trial is BrainStorm currently conducting?
BrainStorm is conducting the Phase 3b ENDURANCE trial to further validate the efficacy and safety of NurOwn in early-stage ALS patients.
What recent data has been shared by BrainStorm?
BrainStorm has reported promising survival data from participants who demonstrated extended survival beyond five years following ALS symptom onset.
How does NurOwn® work?
NurOwn technology utilizes modified mesenchymal stem cells to produce neurotrophic factors, aiming to enhance neurological function and target pathways involved in ALS.
